Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market report penciled down by Extent Research has all the industrial and regional profile along with the market growth initiators details comprehensively provided. The Targeted Drug EGFR RTK Inhibitors for NSCLC market report has also been affected by the recent COVID-19 pandemic but believes to bounce back within a few months. The market is expected to head toward growth during the forecast period through the meticulous market strategies and other stimulating factors. The research report on the global Targeted Drug EGFR RTK Inhibitors for NSCLC market provides a complete overview of the key market, key market players, regional distribution, applications, historical data, and future scope. The key players Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Beacon Pharmaceuticals, Boehringer Ingelheim, Pfizer, ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Drug International Limted, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited, Cipla Pharma, Dr Reddy’s Laboratories, Zydus Cadila, Hetero Drugs, Intas Pharmaceuticals, Alkem Laboratories, RPG Life Sciences, Fresenius Kabi India, provide a complete market valuation and growth scenario.

Data provided by Extent Research. Source: https://www.extentresearch.com/targeted-drug-egfr-rtk-inhibitors-for-nsclc-market

The report intensively covers the significant market study using primary or secondary resources and various research methodologies. The data presented in the report also includes region analysis, market stimulators, opportunities & restraints, forecast scope, strategic planning, and a section allotted for the impact of Covid-19 on the market. The regional distribution presents North America, Europe, Asia Pacific, Latin America, Middle East & Africa that help better understand the market revenue, consumer preference, market scope, and future growth rate. The historical, present, and future numerical and theoretical market analysis are well evaluated and presented through thesis, graphs, pie or bar charts, tables, and pictorial representations for gaining better market knowledge.

Amid the COVID-9 pandemic, the Targeted Drug EGFR RTK Inhibitors for NSCLC market is witnessing immense changes in its entire system. The comprehensive and in-depth study of the market growth rate, volume, share, revenue, and size provide intensified business expanding and financial stand of the market across the globe. The Targeted Drug EGFR RTK Inhibitors for NSCLC market also enforces the risks and challenges faced by the industrial players in the market to obtain better market advancing solutions. Furthermore, the recent technological developments, market strategies, industrial policies, pricing analysis, supply/demand chain, and production analysis are found to have a decisive role in influencing the competitiveness of the market players.

Segmentation of the Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market:

By Product type

Icotinib, Gefitinib, Erlotinib, Afatinib, Osimertinib, Brigatinib, Other,

by Application

Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC,

Report Scope and Market Segmentation

ATTRIBUTES	Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2035
        1.2.2 Icotinib
        1.2.3 Gefitinib
        1.2.4 Erlotinib
        1.2.5 Afatinib
        1.2.6 Osimertinib
        1.2.7 Brigatinib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2035
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2017-2035)
    2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Region
        2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2035
        2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Region (2017-2022)
        2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2035)
    2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Dynamics
        2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Trends
        2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
        2.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
        2.3.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2017-2022)
        3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2017-2022)
    3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
    3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2021
    3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2017-2022)
    4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2035)
5 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Application (2017-2022)
    5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2035)
6 North America
    6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2035)
    6.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        6.2.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        6.2.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2035)
        6.2.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2035)
    6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        6.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        6.3.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2035)
        6.3.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2035)
    6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        6.4.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        6.4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2035)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2035)
    7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        7.2.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2035)
        7.2.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2035)
    7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        7.3.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2035)
        7.3.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2035)
    7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        7.4.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2035)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2035)
    8.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2035)
        8.2.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2035)
    8.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2035)
        8.3.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2035)
    8.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2023-2035)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2035)
    9.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        9.2.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2035)
        9.2.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2035)
    9.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        9.3.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2035)
        9.3.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2035)
    9.4 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        9.4.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2035)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2035)
    10.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2035)
        10.2.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2035)
    10.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2035)
        10.3.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2035)
    10.4 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2035)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Beta Pharma
        11.1.1 Beta Pharma Company Details
        11.1.2 Beta Pharma Business Overview
        11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.1.5 Beta Pharma Recent Developments
    11.2 AstraZeneca
        11.2.1 AstraZeneca Company Details
        11.2.2 AstraZeneca Business Overview
        11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.2.5 AstraZeneca Recent Developments
    11.3 Natco Pharma
        11.3.1 Natco Pharma Company Details
        11.3.2 Natco Pharma Business Overview
        11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.3.5 Natco Pharma Recent Developments
    11.4 Qilu Pharmaceutical
        11.4.1 Qilu Pharmaceutical Company Details
        11.4.2 Qilu Pharmaceutical Business Overview
        11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.4.5 Qilu Pharmaceutical Recent Developments
    11.5 Genentech (Roche Group)
        11.5.1 Genentech (Roche Group) Company Details
        11.5.2 Genentech (Roche Group) Business Overview
        11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.5.5 Genentech (Roche Group) Recent Developments
    11.6 Mylan
        11.6.1 Mylan Company Details
        11.6.2 Mylan Business Overview
        11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.6.5 Mylan Recent Developments
    11.7 Teva
        11.7.1 Teva Company Details
        11.7.2 Teva Business Overview
        11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.7.5 Teva Recent Developments
    11.8 OSI Pharmaceuticals
        11.8.1 OSI Pharmaceuticals Company Details
        11.8.2 OSI Pharmaceuticals Business Overview
        11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.8.5 OSI Pharmaceuticals Recent Developments
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.9.5 Glenmark Pharmaceuticals Recent Developments
    11.10 Beacon Pharmaceuticals
        11.10.1 Beacon Pharmaceuticals Company Details
        11.10.2 Beacon Pharmaceuticals Business Overview
        11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.10.5 Beacon Pharmaceuticals Recent Developments
    11.11 Boehringer Ingelheim
        11.11.1 Boehringer Ingelheim Company Details
        11.11.2 Boehringer Ingelheim Business Overview
        11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.11.5 Boehringer Ingelheim Recent Developments
    11.12 Pfizer
        11.12.1 Pfizer Company Details
        11.12.2 Pfizer Business Overview
        11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.12.5 Pfizer Recent Developments
    11.13 ARIAD Pharmaceuticals (Takeda)
        11.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
        11.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview
        11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.13.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
    11.14 Genvio Pharma Limited
        11.14.1 Genvio Pharma Limited Company Details
        11.14.2 Genvio Pharma Limited Business Overview
        11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.14.5 Genvio Pharma Limited Recent Developments
    11.15 Drug International Limted
        11.15.1 Drug International Limted Company Details
        11.15.2 Drug International Limted Business Overview
        11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.15.5 Drug International Limted Recent Developments
    11.16 Everest Pharmaceuticals
        11.16.1 Everest Pharmaceuticals Company Details
        11.16.2 Everest Pharmaceuticals Business Overview
        11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.16.5 Everest Pharmaceuticals Recent Developments
    11.17 Incepta Pharmaceuticals Limited
        11.17.1 Incepta Pharmaceuticals Limited Company Details
        11.17.2 Incepta Pharmaceuticals Limited Business Overview
        11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.17.5 Incepta Pharmaceuticals Limited Recent Developments
    11.18 Cipla Pharma
        11.18.1 Cipla Pharma Company Details
        11.18.2 Cipla Pharma Business Overview
        11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.18.5 Cipla Pharma Recent Developments
    11.19 Dr Reddy's Laboratories
        11.19.1 Dr Reddy's Laboratories Company Details
        11.19.2 Dr Reddy's Laboratories Business Overview
        11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.19.5 Dr Reddy's Laboratories Recent Developments
    11.20 Zydus Cadila
        11.20.1 Zydus Cadila Company Details
        11.20.2 Zydus Cadila Business Overview
        11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.20.5 Zydus Cadila Recent Developments
    11.21 Hetero Drugs
        11.21.1 Hetero Drugs Company Details
        11.21.2 Hetero Drugs Business Overview
        11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.21.5 Hetero Drugs Recent Developments
    11.22 Intas Pharmaceuticals
        11.22.1 Intas Pharmaceuticals Company Details
        11.22.2 Intas Pharmaceuticals Business Overview
        11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.22.5 Intas Pharmaceuticals Recent Developments
    11.23 Alkem Laboratories
        11.23.1 Alkem Laboratories Company Details
        11.23.2 Alkem Laboratories Business Overview
        11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.23.5 Alkem Laboratories Recent Developments
    11.24 RPG Life Sciences
        11.24.1 RPG Life Sciences Company Details
        11.24.2 RPG Life Sciences Business Overview
        11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.24.5 RPG Life Sciences Recent Developments
    11.25 Fresenius Kabi India
        11.25.1 Fresenius Kabi India Company Details
        11.25.2 Fresenius Kabi India Business Overview
        11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.25.5 Fresenius Kabi India Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market